Uraemic toxins and cardiovascular disease: in vitro research versus clinical outcome studies
- PMID: 30792775
- PMCID: PMC6375242
- DOI: 10.1093/ndtplus/sfm024
Uraemic toxins and cardiovascular disease: in vitro research versus clinical outcome studies
Keywords: cardiovascular disease; clinical outcome studies; in vitro; uraemic toxins.
Figures


Similar articles
-
Effect of uraemia on endothelial cell damage is mediated by the integrin linked kinase pathway.J Physiol. 2015 Feb 1;593(3):601-18; discussion 618. doi: 10.1113/jphysiol.2014.283887. Epub 2014 Dec 18. J Physiol. 2015. PMID: 25398526 Free PMC article.
-
In-vitro study on the competitive binding of diflunisal and uraemic toxins to serum albumin and human plasma using a potentiometric ion-probe technique.J Pharm Pharmacol. 2006 Nov;58(11):1467-74. doi: 10.1211/jpp.58.11.0007. J Pharm Pharmacol. 2006. PMID: 17132209
-
Genesis of the uraemic syndrome: role of uraemic toxins.Wien Klin Wochenschr. 1998 Aug 21;110(15):511-20. Wien Klin Wochenschr. 1998. PMID: 9782569 Review.
-
Protein-bound toxins: has the Cinderella of uraemic toxins turned into a princess?Clin Sci (Lond). 2016 Dec 1;130(23):2209-2216. doi: 10.1042/CS20160393. Clin Sci (Lond). 2016. PMID: 27799624 Review.
-
Comparison of the removal of uraemic toxins with medium cut-off and high-flux dialysers: a randomized clinical trial.Nephrol Dial Transplant. 2020 Feb 1;35(2):328-335. doi: 10.1093/ndt/gfz189. Nephrol Dial Transplant. 2020. PMID: 31578564 Clinical Trial.
Cited by
-
The Relationship of Residual Renal Function with Cardiovascular Morbidity in Hemodialysis Patients and the Potential Role of Monocyte Chemoattractant Protein-1.Kidney Dis (Basel). 2018 Feb;4(1):20-28. doi: 10.1159/000484603. Epub 2017 Nov 17. Kidney Dis (Basel). 2018. PMID: 29594139 Free PMC article.
-
Removal of large middle molecules via haemodialysis with medium cut-off membranes at lower blood flow rates: an observational prospective study.BMC Nephrol. 2019 Dec 31;21(1):2. doi: 10.1186/s12882-019-1669-3. BMC Nephrol. 2019. PMID: 31892319 Free PMC article. Clinical Trial.
-
In Vitro Induction of Eryptosis by Uremic Toxins and Inflammation Mediators in Healthy Red Blood Cells.J Clin Med. 2022 Sep 10;11(18):5329. doi: 10.3390/jcm11185329. J Clin Med. 2022. PMID: 36142976 Free PMC article.
-
The relationship between glycemic control, beta2-microglobulin and inflammation in patients on maintenance dialysis treatment.J Diabetes Metab Disord. 2015 Apr 23;14:34. doi: 10.1186/s40200-015-0162-1. eCollection 2015. J Diabetes Metab Disord. 2015. PMID: 25922828 Free PMC article.
-
High cut-off dialysis mitigates pro-calcific effects of plasma on vascular progenitor cells.Sci Rep. 2021 Jan 13;11(1):1144. doi: 10.1038/s41598-020-80016-7. Sci Rep. 2021. PMID: 33441772 Free PMC article. Clinical Trial.
References
-
- Lindner A, Charra B, Sherrard DJ, et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697–701. - PubMed
-
- Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9:S16–S23. - PubMed
-
- Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005;20:1048–1056. - PubMed
-
- Van Biesen W, De Bacquer D, Verbeke F, et al. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J. 2007;28:478–483. - PubMed
-
- Briet M, Bozec E, Laurent S, et al. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int. 2006;69:350–357. - PubMed
Publication types
LinkOut - more resources
Full Text Sources